Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million on August 31, 2023. Transaction is subject to Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and Morris, Nichols, Arsht & Tunnell LLP served as legal advisors to EPI Health, LLC and K&L Gates LLP served as legal advisor to Mayne Pharma Group Limited (ASX:MYX).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.01 AUD | -1.54% | -4.88% | +13.98% |
May. 10 | Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents | MT |
Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.98% | 376M | |
+19.62% | 43.27B | |
+24.52% | 22.92B | |
+20.29% | 15.43B | |
+7.48% | 12.95B | |
+42.51% | 11.83B | |
-8.84% | 6.91B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.13% | 5.55B |
- Stock Market
- Equities
- MYX Stock
- News Mayne Pharma Group Limited
- Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million.